Literature DB >> 2060607

Effects of injury on [3H]putrescine uptake by types I and II cells in rat lung slices.

D Dinsdale1, S G Preston, B Nemery.   

Abstract

The capacity of different lung parenchymal cells to accumulate putrescine was investigated by incubating slices of rat lung in a medium containing the tritiated compound. Quantitative examination of autoradiographs, by electron microscopy, indicated that accumulation of putrescine occurred in both the Type I and Type II cells of the alveolar epithelium. Putrescine uptake was abolished by the addition of spermidine to the medium or by incubating at 0 degrees C. Lung samples from rats dosed with the pneumotoxin O,S,S-trimethyl phosphorodithioate (OSSMeO), which selectively damages Type I pneumocytes, showed a large reduction in the uptake of label by both Type I and Type II cells. This treatment also resulted in an increase in the labeling of alveolar macrophages. Control samples, from undosed rats, were incubated in medium containing tritiated 5-hydroxytryptamine; this compound did not accumulate in epithelial cells but it was concentrated in the endothelium of the alveolar capillaries and in the blood cells within these vessels. The demonstration of putrescine uptake by both Type I and Type II pneumocytes, together with its reduction by dosing with OSSMeO, has vindicated the use of this activity, in lung slices, as an index of damage to the alveolar epithelium.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060607     DOI: 10.1016/0014-4800(91)90032-s

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  2 in total

1.  Kinetics and cellular localisation of putrescine uptake in human lung tissue.

Authors:  P H Hoet; D Dinsdale; C P Lewis; E K Verbeken; J M Lauweryns; B Nemery
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

2.  Putrescine accumulation in human pulmonary tumours.

Authors:  P H Hoet; D Dinsdale; E K Verbeken; M Demedts; B Nemery
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.